Skip to content

Efficacy and safety of cyclophenol combined with remifentanil in fiberoptic bronchoscopy: a prospective, randomized, double-blind, non inferiority trial

Efficacy and safety of cyclophenol combined with remifentanil in fiberoptic bronchoscopy: a prospective, randomized, double-blind, non inferiority trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062763
Enrollment
Unknown
Registered
2022-08-18
Start date
2022-08-25
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

general anesthesia

Interventions

HR group:Cyclophenol
DR group:Dexmedetomidine

Sponsors

Department of Anesthesiology, Liaocheng People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
45 Years to 65 Years

Inclusion criteria

Inclusion criteria: FB patients under moderate sedation; Age 45 to 65 years old; American Society of anesthesiologists (ASA) class I-II; Operation time 90% when inhaling air into the room.

Exclusion criteria

Exclusion criteria: Known local anesthetic allergy history (RF, midazolam, propofol or cyclophosphamide); Previous lung diseases (such as chronic obstructive pulmonary disease (COPD), respiratory failure and asthma); Severe sleep apnea syndrome (apnea hypopnea index >40); Body mass index (BMI) >30 kg/m2; Communication barriers; Have a history of neuropsychiatric disorder, cerebrovascular disease or abnormal liver and kidney function; History of nasopharyngeal surgery; Second or third degree atrioventricular block; Bradycardia (heart rate (HR) < 60 beats / min); Tobacco and alcohol dependence; Participate in other clinical trials within 3 months

Design outcomes

Primary

MeasureTime frame
Success rate of operation completion;

Secondary

MeasureTime frame
Time index;Hemodynamics;Intubation conditions;Minimum oxygen saturation;Patient and bronchoscope doctor satisfaction;Repeated bronchoscopy willingness and adverse reactions;

Countries

China

Contacts

Public ContactBin Wu
474878322@qq.com+86 13869571703

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026